Biomedical Uses of Reactive Sulfur and Selenium in Diagnosis and Care
Official title: Biomedical Applications of Reactive Sulfur and Selenium Species: Diagnosis and Therapuetics
Funded at Wake Forest University · NIH-11333289 · Data updated 2026-11-12
This research explores how reactive sulfur and selenium compounds could help diagnose and treat diseases like Alzheimer’s and cancer in people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | August 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $363,750 |
| NIH project number | 5R35GM155035-03 |
| Project ID | NIH-11333289 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals at risk for or diagnosed with Alzheimer’s disease or related dementias, as well as patients with certain cancers.
✕Less likely to help
Patients without these conditions or those not suitable for experimental diagnostics or therapies may not benefit.
What this research studies
Researchers at Wake Forest University are studying how reactive sulfur and selenium species behave in the body to improve diagnosis and therapy for Alzheimer’s disease and cancer. The project aims to overcome challenges in delivering these reactive compounds to patients and detecting them accurately. By understanding their biological activity, the study hopes to pave the way for new diagnostic tools and treatment approaches that could benefit people with neurodegenerative diseases and cancer.
Why it matters
Potential benefit: If successful, this work could lead to new ways to diagnose Alzheimer’s-related conditions earlier and to develop innovative treatments for neurodegenerative diseases and cancer.
How similar studies have gone: Preclinical studies have shown potential for RSS and RSeS in cancer and neuroprotection, but clinical translation remains limited.
Where this research is happening
-
Wake Forest University
Winston-Salem, United States Active
Researchers
- Principal investigator: Lukesh, John Carl — Wake Forest University
- Study coordinator: Lukesh, John Carl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.